Logo

Amgen Seeks Interchangeable Status for Its Amjevita (biosimilar, adalimumab)

Share this

Amgen Seeks Interchangeable Status for Its Amjevita (biosimilar, adalimumab)

Shots:

  • Amgen plans to seek interchangeable status for its adalimumab biosimilar Amjevita. The company plans to launch Amjevita (biosimilar, adalimumab) in 2023 in the US
  • Amgen reported that patients are currently being enrolled in P-III studies to support interchangeability designation in the US for biosimilars of Amjevita (adalimumab) and ABP 654 (ustekinumab)
  • The company is expected the P-III results shortly for biosimilar Stelara (ustekinumab) to treat PsO and PsA while Eylea (aflibercept) for macular degeneration and Soliris (eculizumab) for PNH and aHUS

Ref: Fierce Pharma | Image: Amgen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions